Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bosentan + dapagliflozin
- Development stage
- Unknown
- Lead developer
- University of Edinburgh
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
bosentan + dapagliflozin is an investigational combination therapy being evaluated for the treatment of large vessel vasculitis (LVV). The combination consists of two small molecule active ingredients: bosentan, a dual endothelin receptor antagonist, and dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This therapeutic approach, spearheaded by the University of Edinburgh, is currently being studied in the Phase 2 DERAIL-LVV trial to assess its impact on endothelial function and arterial stiffness in patients with LVV in remission. By blocking endothelin receptors, bosentan aims to reduce vessel stiffness and blood pressure, while dapagliflozin provides additional vascular protection and may help mitigate the fluid retention often associated with endothelin receptor antagonists. The combination is intended to address the heightened cardiovascular risk in patients with chronic inflammatory vascular disease.
- Other names
- DERAIL-LVV combination
02
Targets
EDNRA (Endothelin receptor type A)EDNRB (Endothelin receptor type B)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on bosentan + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bosentan + dapagliflozin.